Charles A. Signorino, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charles A. Signorino, PhD


Charles A. Signorino, PhD is a Pharmtech editorial advisory board (EAB) member

Charles A. Signorino, PhD
CEO
Emerson Resources, Inc.

Charles A. Signorino is the chief executive officer of Emerson Resources, Inc. He is an adjunct professor of pharmaceutics at the University of the Sciences in Philadelphia, and he has held positions at CS Associates Inc., Colorcon Inc., Eastern College, and Arco Chemical. His areas of expertise are aqueous enteric and film coating technology, FDA-approved colors and applications, pharmaceutical excipients, and rapid sugar coating.

Signorino is a member of the American Association of Pharmaceutical Scientists (AAPS), the American Chemical Society (ACS), and is also a member of the editorial advisory board for American Pharmaceutical Review. He has authored numerous technical publications, and he has given numerous seminars for various industry and academic events.

Signorino holds a BS from Pennsylvania State University, an MS and PhD from the University of Pennsylvania and an MAR from Westminster Theological Seminary.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here